Discontinuation Syndrome With JAK2 Selective Agents: Case Presentation and Mechanistic InsightsShivani Handa(Icahn School of Medicine at Mount Sinai), Alan H. Shih(Tisch Hospital)JCO Precision OncologyJanuary 31, 202410.1200/po.23.00234Cited by 5SaveCiteExport RISWatch citationsRelated PapersLeukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation|Cancer Cell|2010|2.7k